Evidence map›Paper›PMID 30506673›Full record

ArticleClinical pharmacology and therapeutics2019

Genetic Variants Associated With Vincristine-Induced Peripheral Neuropathy in Two Populations of Children With Acute Lymphoblastic Leukemia.

Lang Li, Tammy Sajdyk, Ellen M L Smith, Chien Wei Chang, Claire Li, Richard H Ho, Raymond Hutchinson, Elizabeth Wells, Jodi L Skiles, Naomi Winick and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Future science OA · 2020
    Article
  13. Review
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 1 country.

Lang LiOhio State University, Columbus, Ohio, USA.
Tammy SajdykIndiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0001-7641-3408
Ellen M L SmithUniversity of Michigan, Ann Arbor, Michigan, USA.
Chien Wei ChangOhio State University, Columbus, Ohio, USA.
Claire LiMerck, Upper Gwynedd, Pennsylvania, USA.
Richard H HoVanderbilt University, Nashville, Tennessee, USA.
Raymond HutchinsonUniversity of Michigan, Ann Arbor, Michigan, USA.
Elizabeth WellsChildren's Children Research Institute, Washington, District of Columbia, USA.
Jodi L SkilesIndiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0002-7653-5920
Naomi WinickUniversity of Texas Southwestern Medical Center, Dallas, Texas, USA.
Paul L MartinDuke University Medical Center, Durham, North Carolina, USA.
Jamie L RenbargerIndiana University School of Medicine, Indianapolis, Indiana, USA.
Indiana University School of MedicineThe Ohio State University · USUniversity of Michigan · USChildren’s Institute · USDuke Medical Center · USGwynedd Mercy University · USThe University of Texas Southwestern Medical Center · USVanderbilt University · US

Funding

Pharmacogenetic Determinants of Vincristine Toxicity and ResponseR01HD062484 · NICHD · INDIANA UNIVERSITY INDIANAPOLIS · PI RENBARGER, JAMIE L · 2011 to 2016
$3.1M
Hepatic OATP Drug Transporters and Chemotherapy DispositionR01GM099924 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HO, RICHARD HSINSHIN · 2012 to 2017
$2.0M
NICHD NIH HHS R01 HD062484NIGMS NIH HHS R01 GM099924
6 · The paper itself

Abstract

Vincristine is one of the core chemotherapy agents used in the treatment of pediatric acute lymphoblastic leukemia (ALL). However, one of the major toxicities resulting from vincristine exposure is vincristine-induced peripheral neuropathy (VIPN). When VIPN results in significant morbidity, the vincristine dose may need to be reduced, thus potentially decreasing the effectiveness of treatment. To date, there are no robust biomarkers used clinically to determine which patients will be at risk for worse neuropathy. The current study included genomewide association study (GWAS) in two independent cohorts: Pediatric Oncology Group (POG) ALL trials and a multicenter study based at Indiana University in children with ALL. A meta-analysis of the cohorts identified two single-nucleotide polymorphisms (SNPs), rs1045644 and rs7963521, as being significantly (P value threshold 0.05/4749 = 1.05E-05) associated with neuropathy. Subsequently these SNPs may be effective biomarkers of VIPN in children with ALL.

Indexed as

AdolescentAntineoplastic Agents, PhytogenicChildChild, PreschoolCohort StudiesFemaleGenetic VariationGenome-Wide Association StudyHumansInfantMalePeripheral Nervous System DiseasesPolymorphism, Single NucleotidePrecursor Cell Lymphoblastic Leukemia-LymphomaVincristineYoung AdultAntineoplastic Agents, PhytogenicVincristine

Identifiers

PMID30506673
PMCPMC6513686
OpenAlexW2902258921

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.